RLYB
Rallybio Corp

621
Mkt Cap
$26.37M
Volume
393,951.00
52W High
$1.24
52W Low
$0.2201
PE Ratio
-1.96
RLYB Fundamentals
Price
$0.61
Prev Close
$0.6242
Open
$0.63
50D MA
$0.5937
Beta
1.42
Avg. Volume
309,079.22
EPS (Annual)
-$1.33
P/B
0.42
Rev/Employee
$25,440.00
Loading...
Loading...
News
all
press releases
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported...
Business Wire·14d ago
News Placeholder
More News
News Placeholder
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
Zacks·4mo ago
News Placeholder
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced...
Business Wire·9mo ago
News Placeholder
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced...
Business Wire·9mo ago
News Placeholder
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today...
Business Wire·10mo ago
News Placeholder
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced...
Business Wire·1y ago
News Placeholder
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced...
Business Wire·1y ago
News Placeholder
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced...
Business Wire·1y ago
News Placeholder
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced...
Business Wire·1y ago
News Placeholder
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced...
Business Wire·1y ago

Latest RLYB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.